Company / Free Cash Flow
Dianthus Therapeutics, Inc. /DE/ Free Cash Flow History
FY2016-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Free Cash Flow
-$37.0M
FY2024
5-year range
-$60.8M / -$29.2M
FY2020-FY2024
Trend
+0.0%
vs FY2023
Sector context
#75 of 194
Health Care
What the data says
At -$37M, Dianthus Therapeutics, Inc. /DE/'s free cash flow ranks #75 of 194 in the Health Care sector. Declined from -$29M to -$37M over the past 2 years.
Based on SEC 10-K filings.
-$37M in FY2024.
Declined from -$29M to -$37M over the past 2 years.
Health Care sector context is included.
Free Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#75 of 194 in Health CareTop 39% of 194This company -$37.0M Sector average $470.8M
▼
-107.9% below sector average
Key checks
Key Insights
- In FY2024, free cash flow increased 0.0% year-over-year.
- Ranks #75 out of 194 companies in the Health Care sector.
- Peak free cash flow was recorded in FY2016.
- Lowest free cash flow in the period was in FY2020.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 4.46 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Free Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | -$37.0M | +0.0% |
| FY2023 | -$37.0M | -26.6% |
| FY2022 | -$29.2M | +52.0% |
| FY2021 | -$60.8M | +5.6% |
| FY2020 | -$64.4M | -7.1% |
| FY2019 | -$60.2M | -21.4% |
| FY2018 | -$49.6M | -102.6% |
| FY2017 | -$24.5M | -266.9% |
| FY2016 | -$6.7M | - |
As of FY2024 · SEC 10-K · Updated Jun 30, 2026